Ribociclib
Sign in to save this workspacePrimary targets: CDK4_CYCLIN_D1, CDK4_CYCLIN_D3, CDK4_CYCLIN_D2, CDK6_CYCLIN_D1, CDK6_CYCLIN_D3, CDK6_CYCLIN_D2 · FDA status: FDA Approved
Selectivity scorecard
KISS
99.25
Gini
0.729
CATDS
0.039
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Ribociclib. Strongest target: CDK4_CYCLIN_D3 at 98.6% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | CDK4_CYCLIN_D3 | 98.6% | 1.4% |
| 2 | CDK6_CYCLIN_D1 | 95.3% | 4.7% |
| 3 | CDK4_CYCLIN_D1 | 94.7% | 5.3% |
| 4 | CDK6_CYCLIN_D3 | 73.3% | 26.7% |
| 5 | CAMK2B | 59.0% | 41.0% |
| 6 | CDK8_CYCLIN_C | 55.6% | 44.4% |
| 7 | CAMK2D | 54.3% | 45.7% |
| 8 | LIMK1 | 51.0% | 49.0% |
| 9 | SIK2 | 48.8% | 51.2% |
| 10 | CDK9_CYCLIN_T2 | 46.5% | 53.5% |
| 11 | CDK19_CYCLIN_C | 46.5% | 53.5% |
| 12 | AURORA_C | 43.1% | 56.9% |
| 13 | CDK9_CYCLIN_T1 | 41.6% | 58.4% |
| 14 | CAMKK2 | 39.5% | 60.5% |
| 15 | DAPK2 | 31.6% | 68.4% |
| 16 | ERK7_MAPK15 | 31.2% | 68.8% |
| 17 | TNK1 | 30.8% | 69.2% |
| 18 | PDK2_PDHK2 | 28.4% | 71.6% |
| 19 | LYN | 24.5% | 75.5% |
| 20 | HASPIN | 24.3% | 75.7% |
Selectivity landscape
Where Ribociclib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Ribociclib.
Atlas insights for Ribociclib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 569.22 | |
| ALLOGRAFT_REJECTION | 1591.26 | |
| ANDROGEN_RESPONSE | 691.63 | |
| ANGIOGENESIS | 203.87 | |
| APICAL_JUNCTION | 1599.64 | |
| APICAL_SURFACE | 132.10 | |
| APOPTOSIS | 1674.15 | |
| BILE_ACID_METABOLISM | 177.37 | |
| CHOLESTEROL_HOMEOSTASIS | 268.01 | |
| COAGULATION | 133.57 | |
| COMPLEMENT | 1011.71 | |
| DNA_REPAIR | 345.02 | |
| E2F_TARGETS | 1258.08 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 716.62 | |
| ESTROGEN_RESPONSE_EARLY | 781.11 | |
| ESTROGEN_RESPONSE_LATE | 623.74 | |
| FATTY_ACID_METABOLISM | 192.47 | |
| G2M_CHECKPOINT | 1028.16 | |
| GLYCOLYSIS | 536.63 | |
| HEDGEHOG_SIGNALING | 198.56 | |
| HEME_METABOLISM | 333.35 | |
| HYPOXIA | 819.96 | |
| IL2_STAT5_SIGNALING | 454.13 | |
| IL6_JAK_STAT3_SIGNALING | 794.21 | |
| INFLAMMATORY_RESPONSE | 917.81 | |
| INTERFERON_ALPHA_RESPONSE | 185.04 | |
| INTERFERON_GAMMA_RESPONSE | 1104.64 | |
| KRAS_SIGNALING_DN | 246.78 | |
| KRAS_SIGNALING_UP | 589.78 | |
| MITOTIC_SPINDLE | 1296.41 | |
| MTORC1_SIGNALING | 859.53 | |
| MYC_TARGETS_V1 | 772.56 | |
| MYC_TARGETS_V2 | 203.95 | |
| MYOGENESIS | 656.96 | |
| NOTCH_SIGNALING | 89.74 | |
| OXIDATIVE_PHOSPHORYLATION | 249.52 | |
| P53_PATHWAY | 682.46 | |
| PANCREAS_BETA_CELLS | 62.92 | |
| PEROXISOME | 175.19 | |
| PI3K_AKT_MTOR_SIGNALING | 1833.18 | |
| PROTEIN_SECRETION | 455.42 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 40.77 | |
| SPERMATOGENESIS | 425.73 | |
| TGF_BETA_SIGNALING | 377.68 | |
| TNFA_SIGNALING_VIA_NFKB | 928.21 | |
| UNFOLDED_PROTEIN_RESPONSE | 349.23 | |
| UV_RESPONSE_DN | 827.29 | |
| UV_RESPONSE_UP | 778.52 | |
| WNT_BETA_CATENIN_SIGNALING | 534.43 | |
| XENOBIOTIC_METABOLISM | 418.43 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.862 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.848 |
| SRR23303752 | — | 0.844 |
| TCGA-FD-A43X-01A-11R-A23W-07 | — | 0.834 |
| SRR12202498 | — | 0.832 |
Annotations
Sign in to read and post annotations.
Loading…